Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism
Open Access
- 27 November 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (3) , 2765-2779
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Lianne E. Rotin1, 2, Marcela Gronda1, Neil MacLean1, Rose Hurren1, XiaoMing Wang1, Feng-Hsu Lin1, Jeff Wrana3, Alessandro Datti3, 4, Dwayne L. Barber1, Mark D. Minden1, 2, Malik Slassi5, Aaron D. Schimmer1, 2 1Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada 2Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada 3Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada 4Department of Agricultural, Food, and Environmental Sciences, University of Perugia, Perugia, Italy 5Fluorinov Pharma Inc., Toronto, Ontario, Canada Correspondence to: Aaron D. Schimmer, e-mail: aaron.schimmer@utoronto.ca Keywords: AML, BTK, ibrutinib, ethacridine lactate, PARG Received: July 29, 2015 Accepted: November 16, 2015 Published: November 27, 2015 ABSTRACT Targeting Bruton’s tyrosine kinase (BTK) with the small molecule BTK inhibitor ibrutinib has significantly improved patient outcomes in several B-cell malignancies, with minimal toxicity. Given the reported expression and constitutive activation of BTK in acute myeloid leukemia (AML) cells, there has been recent interest in investigating the anti-AML activity of ibrutinib. We noted that ibrutinib had limited single-agent toxicity in a panel of AML cell lines and primary AML samples, and therefore sought to identify ibrutinib-sensitizing drugs. Using a high-throughput combination chemical screen, we identified that the poly(ADP-ribose) glycohydrolase (PARG) inhibitor ethacridine lactate synergized with ibrutinib in TEX and OCI-AML2 leukemia cell lines. The combination of ibrutinib and ethacridine induced a synergistic increase in reactive oxygen species that was functionally important to explain the observed cell death. Interestingly, synergistic cytotoxicity of ibrutinib and ethacridine was independent of the inhibitory effect of ibrutinib against BTK, as knockdown of BTK did not sensitize TEX and OCI-AML2 cells to ethacridine treatment. Thus, our findings indicate that ibrutinib may have a BTK-independent role in AML and that PARG inhibitors may have utility as part of a combination therapy for this disease.Keywords
This publication has 47 references indexed in Scilit:
- Ibrutinib and novel BTK inhibitors in clinical developmentJournal of Hematology & Oncology, 2013
- PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathwaysCell Death & Disease, 2013
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerJournal of Hematology & Oncology, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- DNA Damage in Nijmegen Breakage Syndrome Cells Leads to PARP Hyperactivation and Increased Oxidative StressPLOS Genetics, 2012
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1Genes & Development, 2012
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010
- Dual role of poly(ADP‐ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cellsThe FASEB Journal, 2009
- Mono‐galloyl glucose derivatives are potent poly(ADP‐ribose) glycohydrolase (PARG) inhibitors and partially reduce PARP‐1‐dependent cell deathBritish Journal of Pharmacology, 2008